LG Chem Confirms Optimal Dose for Ficlatuzumab in Global Phase 3 Head and Neck Cancer Trial
LG Chem said it has finalized the optimal dosing level for its investigational anticancer drug ficlatuzumab in an ongoing global Phase 3 clinical trial. On February 20, the company announced that its U.S. subsidiary, AVEO Pharmaceuticals, will proceed with …